Skip to main content
. Author manuscript; available in PMC: 2013 Oct 23.
Published in final edited form as: Pancreatology. 2012 Jun 15;12(4):358–363. doi: 10.1016/j.pan.2012.05.011

Table 2.

Pre-IPMN Extra-pancreatic Malignancy Type and Frequency.a

All patients
(72 pts, 77 tumors)
PFH (16 pts,
17 tumors)
NFH
(56 pts, 60 tumors)
Breast 16 (20.8) 6 (35.3) 10 (16.7)
Prostate 14 (18.2) 1 (5.9) 13 (21.7)
Gynecologic 9 (11.7) 2 (11.8) 7 (11.7)
Skin 7 (9.1) 3 (17.6) 4 (6.7)
Bladder 5 (6.5) 0 (0) 5 (8.3)
Colorectal 5 (6.5) 2 (11.8) 3 (5.0)
Lymphoma/Leukemia 5 (6.5) 1 (5.9) 4 (6.7)
Lung 4 (5.2) 1 (5.9) 3 (5.0)
Thyroid 2 (2.6) 0 (0) 2 (3.3)
Renal 2 (2.6) 1 (5.9) 1 (1.7)
Other 8 (10.4) 0 (0) 8 (13.3)
a

Data presented as number of patients (percentage).